Assetmark Inc. Has $1.04 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Assetmark Inc. lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.8% during the third quarter, Holdings Channel.com reports. The firm owned 33,442 shares of the specialty pharmaceutical company’s stock after buying an additional 908 shares during the quarter. Assetmark Inc.’s holdings in Supernus Pharmaceuticals were worth $1,043,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Armistice Capital LLC increased its position in Supernus Pharmaceuticals by 47.6% during the 2nd quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock worth $141,026,000 after buying an additional 1,700,000 shares during the period. Pacer Advisors Inc. increased its position in Supernus Pharmaceuticals by 100,186.3% during the second quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock worth $36,109,000 after acquiring an additional 1,348,508 shares during the period. American Century Companies Inc. raised its stake in Supernus Pharmaceuticals by 369.1% in the 2nd quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company’s stock worth $13,419,000 after purchasing an additional 394,728 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Supernus Pharmaceuticals by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after purchasing an additional 351,900 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Supernus Pharmaceuticals by 12.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after purchasing an additional 309,966 shares in the last quarter.

Wall Street Analysts Forecast Growth

SUPN has been the subject of a number of analyst reports. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Insider Buying and Selling

In related news, SVP Frank Mottola sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now directly owns 8,200 shares of the company’s stock, valued at approximately $303,236. The trade was a 64.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. This represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock worth $5,660,180 in the last ninety days. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Trading Down 4.2 %

Shares of Supernus Pharmaceuticals stock opened at $36.18 on Friday. The company has a market cap of $2.00 billion, a PE ratio of 33.81 and a beta of 0.86. The company has a 50 day moving average of $33.32 and a 200-day moving average of $30.88. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company’s revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) earnings per share. Research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.